grant
Cancer Immunology
Organization FRED HUTCHINSON CANCER CENTERLocation SEATTLE, UNITED STATESPosted 1 Jan 1997Deadline 31 Dec 2029
NIHUS FederalResearch GrantFY20260-11 years old21+ years oldAchievementAchievement AttainmentAddressAdultAdult HumanAdvanced CancerAdvanced Malignant NeoplasmAntigensAreaB-Cell Attracting Chemokine 1B-Lymphocyte ChemoattractantBCA1BLC geneBLC proteinBiologyBiomedical EngineeringBreast CancerCAR T cellsCAR modified T cellsCAR-TCAR-TsCCSGCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCNS TumorCNS neoplasmCXCL13CXCL13 geneCancer Center Support GrantCancer ModelCancer PatientCancerModelCancersCell BodyCell TherapyCellsCentral Nervous System NeoplasmsCentral Nervous System TumorsChemokine, CXC Motif, Ligand 13ChildChild YouthChildhoodChildhood CancersChildhood NeoplasmChildhood TumorChildren (0-21)ClinicalClinical TrialsCollaborationsComplexData AnalysesData AnalysisDeath RateDedicationsDevelopmentDiseaseDisorderFundingFutureGene ModifiedGeneralized GrowthGenesGrantGrowthHSC transplantationHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoietic CancerHematopoietic Stem Cell TransplantHematopoietic Stem Cell TransplantationHumanImmuneImmune mediated therapyImmunesImmunochemical ImmunologicImmunologicImmunologicalImmunologicallyImmunologically Directed TherapyImmunologicsImmunologyImmunotherapyIncidenceInfiltrationInflammationInfusionInfusion proceduresInstitutionMHC ReceptorMajor Histocompatibility Complex ReceptorMalignant Breast NeoplasmMalignant CellMalignant Childhood NeoplasmMalignant Childhood TumorMalignant Hematologic NeoplasmMalignant MelanomaMalignant NeoplasmsMalignant Ovarian NeoplasmMalignant Ovarian TumorMalignant Pediatric NeoplasmMalignant Pediatric TumorMalignant TumorMalignant Tumor of the OvaryMalignant childhood cancerMalignant neoplasm of ovaryMediatingMelanomaMethodsModelingModern ManNephroblastomaOutcomes ResearchOvary CancerPaperPediatric NeoplasmPediatric TumorPhenotypePopulationPre-Clinical ModelPreclinical ModelsProductionProtein EngineeringPublicationsPublishingRecurrenceRecurrentRefractoryRegulatory T-LymphocyteRelapseRenal Wilms' TumorResearchResearch SpecimenSCYB13Scientific PublicationSecureSmall Inducible Cytokine Subfamily B, Member 13Solid NeoplasmSolid TumorSpecimenT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell receptor based immunotherapyT cell receptor cellular immunotherapyT cell receptor engineered therapyT cell receptor immunotherapyT cell responseT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cells for CART cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-Cell Antigen ReceptorsT-Cell DevelopmentT-Cell OntogenyT-Cell ReceptorT-Cell Receptor TherapyT-Cell Receptor TreatmentT-Cell Receptor based TherapyT-Cell Receptor based TreatmentT-CellsT-LymphocyteT-Lymphocyte DevelopmentT-cell therapeuticsT-cell transfer therapyT4 CellsT4 LymphocytesTCR T cell immunotherapyTCR T cell therapyTCR TherapyTCR based T cell immunotherapyTCR based TherapyTCR based immune therapyTCR based immunotherapyTCR based treatmentTCR immunotherapyTechnologyTissue GrowthTranslatingTranslational ResearchTranslational Research EnterpriseTranslational ScienceTregWAGRWT1WT1 Gene ProductWT1 ProteinWT1 geneWT33WashingtonWilm's TumorWilms TumorWilms Tumor 1Wilms tumor suppressor WT1Wilms' Tumor of the Kidneyadoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyadulthoodanalytical methodanti-cancer immunotherapyanticancer immunotherapyantigen-specific T cellsbio-engineeredbio-engineersbioengineeringbiological engineeringblood stem cell transplantationcancer carecancer cellcancer immunologycancer immunotherapycancer in a childcancer in childrencancer microenvironmentcell based interventioncell mediated interventioncell mediated therapiescell-based therapeuticcell-based therapycellular therapeuticcellular therapycheck point blockadecheckpoint blockadechild with cancerchildhood malignancychimeric antigen T cell receptorchimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cellschimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsclinical applicabilityclinical applicationclinical practicecost effectivedata interpretationdevelopmentalengineered T cellsexperiencefirst in manfirst-in-humangene modificationgenetic protein engineeringgenetically engineered T-cellsgenetically modifiedhematopoietic cell transplantationhematopoietic cellular transplantationhematopoietic progenitor cell transplantationhigh dimensionalityimmune check point blockadeimmune checkpoint blockadeimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based cancer therapiesimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenimmunotherapy for cancerimmunotherapy of cancerin vivoinfusionsinnovateinnovationinnovativeinterestkidsmalignancymalignant breast tumormeetingmeetingsmembermortality ratenanocarriernanovesselneo-antigenneo-epitopesneoantigensneoepitopesneoplasm immunologyneoplasm/cancernovelontogenyovarian cancerpathogenpediatricpediatric cancerpediatric malignancypreventpreventingprogramsprotein designrecruitregulatory T-cellssafety and feasibilitysuccesssynthetic biologytherapeutic T-cell platformthymus derived lymphocytetransgenic T- cellstranslation researchtranslation research enterprisetranslational investigationtranslational research programtumortumor eradicationtumor immunologytumor microenvironmenttumor of the central nervous systemtumors in childrentumors in the central nervous systemyoungster
Description preview
PROJECT SUMMARY
The Cancer Immunology (CI) Program is dedicated to basic, translational, and clinical cancer immunology research, with a strong emphasis on developing T cell immunotherapy, including genetically modified CAR-T and TCR-T therapies. Over the recent grant cycle, the program has published over 82 high-impact papers (2020- 2023) and…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click